The pharmaceutical industry is upset with the French government's decision to introduce a measure that would permit pharmacists to substitute branded biotech drugs with cheaper biosimilar versions. The proposal, which still needs a decree to take effect, would turn France into a less-attractive investment destination for drugmakers, said Philippe Lamoureux, head of pharmaceutical trade group Leem. Major drugmakers including Roche, Sanofi and Amgen are discussing the details of the decree with government officials, physicians and pharmacists.

Full Story:

Related Summaries